Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 2/2002

01-04-2002 | ORIGINAL ARTICLE

NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese

Authors: N. Hamajima, K. Matsuo, H. Iwata, M. Shinoda, Y. Yamamura, T. Kato, S. Hatooka, T. Mitsudomi, M. Suyama, Y. Kagami, M. Ogura, M. Ando, Y. Sugimura, K. Tajima

Published in: International Journal of Clinical Oncology | Issue 2/2002

Login to get access
Metadata
Title
NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese
Authors
N. Hamajima
K. Matsuo
H. Iwata
M. Shinoda
Y. Yamamura
T. Kato
S. Hatooka
T. Mitsudomi
M. Suyama
Y. Kagami
M. Ogura
M. Ando
Y. Sugimura
K. Tajima
Publication date
01-04-2002
Publisher
Springer-Verlag
Published in
International Journal of Clinical Oncology / Issue 2/2002
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s101470200013

Other articles of this Issue 2/2002

International Journal of Clinical Oncology 2/2002 Go to the issue

ORIGINAL ARTICLE

Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer

REVIEW ARTICLE

Current and future trends in management and treatment of Klatskin tumour

ORIGINAL ARTICLE

Preoperative parameters to predict tumor volume in Japanese patients with nonpalpable prostate cancer

CASE REPORT

Renal angiomyolipoma with minimal fat

CASE REPORT

Severe gustatory disorder caused by cisplatin and etoposide

REVIEW ARTICLE

Radiofrequency ablation of primary and metastatic hepatic malignancies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits